Structured evidence table for Zinc Blood Pressure Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Zinc Blood Pressure Randomized Trial | Hypertension represents the predominant risk factor for cardiovascular disease morbidity and mortality; with significant healthcare utilization and expenditure. | 2 | Sinclair J (2026) | Effects of peppermint (Mentha x piperita L.) oil on cardiometabolic outcomes in patients with pre- and stage 1 hypertension: A placebo randomized controlled trial. |
| Zinc Blood Pressure Randomized Trial | Given the substantial health and economic burden associated with hypertension worldwide, these findings suggest that twice-daily peppermint supplementation may represent a simple, low-cost, and well-tolerated strategy to support blood pressure reduction in this population. | 2 | Sinclair J (2026) | Effects of peppermint (Mentha x piperita L.) oil on cardiometabolic outcomes in patients with pre- and stage 1 hypertension: A placebo randomized controlled trial. |
| Zinc Blood Pressure Randomized Trial | Pharmaceutical management is habitually adopted; although its long-term effectiveness remains ambiguous, and accompanying adverse effects are disquieting. | 2 | Sinclair J (2026) | Effects of peppermint (Mentha x piperita L.) oil on cardiometabolic outcomes in patients with pre- and stage 1 hypertension: A placebo randomized controlled trial. |
| Zinc Blood Pressure Randomized Trial | Importantly, while elevated intraocular pressure (IOP) is a well-established risk factor and the only available treatment target, it is neither necessary nor sufficient for the development of glaucoma, as evidenced by the existence of normal-tension glaucoma and the observation that many patients continue to progress despite achieving target IOP levels. | 3 | Hui Flora (2026) | Vitamins and nutraceuticals in glaucoma research |
| Zinc Blood Pressure Randomized Trial | It is estimated that the number of individuals affected by glaucoma will continue to rise, with substantial socioeconomic impact due to vision loss and associated disability.Age is the most prominent risk factor, but genetic predisposition, vascular dysregulation, and systemic metabolic dysfunction have also been implicated in disease susceptibility and progression. | 3 | Hui Flora (2026) | Vitamins and nutraceuticals in glaucoma research |
| Zinc Blood Pressure Randomized Trial | Studies suggest that up to 28% of retinal ganglion cells may be lost before early visual field defects become apparent.Advances in imaging, home-based visual field monitoring, and artificial intelligence-assisted analysis are being developed to improve early detection and risk stratification, but challenges remain in predicting individual disease trajectories. | 3 | Hui Flora (2026) | Vitamins and nutraceuticals in glaucoma research |
| Zinc Blood Pressure Randomized Trial | 1 2 , Glaucoma is a common neurodegenerative disease characterized by the degeneration of retinal ganglion cells and their axons, leading to characteristic structural changes at the optic nerve head and corresponding visual field loss. | 3 | Hui Flora (2026) | Vitamins and nutraceuticals in glaucoma research |
Source documents